Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS.

Staff NP., Madigan NN., Morris J., Jentoft M., Sorenson EJ., Butler G.

Clinical Trial on Back & Spine, published in Neurology (2016) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Neurology (2016)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
27784774
PMCID
PMC5123559
DOI
10.1212/WNL.0000000000003359
Citations
93

Abstract (original English)

Objective To determine the safety of intrathecal autologous adipose-derived mesenchymal stromal cell treatment for amyotrophic lateral sclerosis (ALS). Methods Participants with ALS were enrolled and treated in this phase I dose-escalation safety trial, ranging from 1 × 10 7 (single dose) to 1 × 10 8 cells (2 monthly doses). After intrathecal treatments, participants underwent standardized follow-up, which included clinical examinations, revised ALS Functional Rating Scale (ALSFRS-R) questionnaire, blood and CSF sampling, and MRI of the neuroaxis. Results Twenty-seven patients with ALS were enrolled and treated in this study. The safety profile was positive, with the most common side effects reported being temporary low back and radicular leg pain at the highest dose level. These clinical findings were associated with elevated CSF protein and nucleated cells with MRI of thickened lumbosacral nerve roots. Autopsies from 4 treated patients did not show evidence of tumor formation. Longitudinal ALSFRS-R questionnaires confirmed continued progression of disease in all treated patients. Conclusions Intrathecal treatment of autologous adipose-derived mesenchymal stromal cells appears safe at the tested doses in ALS. These results warrant further exploration of efficacy in phase II trials. Classification of evidence This phase I study provides Class IV evidence that in patient with AL

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AdipocytesAdultAgedAmyotrophic Lateral SclerosisBiomarkersBrainFemaleFollow-Up StudiesHumansInjections, Spinal

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research